237 related articles for article (PubMed ID: 29631131)
1. Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients.
Intravooth T; Staack AM; Juerges K; Stockinger J; Steinhoff BJ
Epilepsy Res; 2018 Jul; 143():7-10. PubMed ID: 29631131
[TBL] [Abstract][Full Text] [Related]
2. [Long-term effects of dibenzazepines on metabolic parameters: retrospective comparison of carbamazepine, oxcarbazepine and eslicarbazepine acetate in the real world].
Ley M; Principe A; Rocamora R
Rev Neurol; 2020 Jul; 71(2):54-60. PubMed ID: 32627160
[TBL] [Abstract][Full Text] [Related]
3. Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review.
Rissardo JP; Caprara ALF
Clin Neuropharmacol; 2020; 43(3):66-80. PubMed ID: 32384309
[TBL] [Abstract][Full Text] [Related]
4. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.
Peltola J; Holtkamp M; Rocamora R; Ryvlin P; Sieradzan K; Villanueva V
Epilepsy Behav; 2015 Sep; 50():46-9. PubMed ID: 26114438
[TBL] [Abstract][Full Text] [Related]
5. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
6. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
Berghuis B; van der Palen J; de Haan GJ; Lindhout D; Koeleman BPC; Sander JW;
Epilepsia; 2017 Jul; 58(7):1227-1233. PubMed ID: 28542738
[TBL] [Abstract][Full Text] [Related]
7. Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
Berghuis B; Hulst J; Sonsma A; McCormack M; de Haan GJ; Sander JW; Lindhout D; Koeleman BPC
Epilepsia; 2021 Mar; 62(3):778-784. PubMed ID: 33576502
[TBL] [Abstract][Full Text] [Related]
8. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Schmid E; Kuchukhidze G; Kirschner M; Leitinger M; Höfler J; Rohracher A; Kalss G; Wendling AS; Steinhoff BJ; Trinka E
Acta Neurol Scand; 2017 Apr; 135(4):449-453. PubMed ID: 27444636
[TBL] [Abstract][Full Text] [Related]
9. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
[TBL] [Abstract][Full Text] [Related]
10. EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy.
Villanueva V; Ojeda J; Rocamora RA; Serrano-Castro PJ; Parra J; Rodríguez-Uranga JJ; Bathal H; Viteri C
Neurologia (Engl Ed); 2018 Jun; 33(5):290-300. PubMed ID: 27349151
[TBL] [Abstract][Full Text] [Related]
11. Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
Mäkinen J; Rainesalo S; Peltola J
Brain Behav; 2017 Mar; 7(3):e00634. PubMed ID: 28293474
[TBL] [Abstract][Full Text] [Related]
12. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.
Massot A; Vivanco R; Principe A; Roquer J; Rocamora R
Neurologia; 2014 Mar; 29(2):94-101. PubMed ID: 23623701
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital.
Lee JE; Min KR; Kim SH; Kim AH; Kim ST
Yonsei Med J; 2020 Oct; 61(10):875-879. PubMed ID: 32975062
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
16. [A proposal for a model to replace carbamazepine or oxcarbazepine by eslicarbazepine acetate in clinical practice].
Poza-Aldea JJ
Rev Neurol; 2016 Sep; 63(5):219-23. PubMed ID: 27569568
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
[TBL] [Abstract][Full Text] [Related]
18. Hyponatremic coma under oxcarbazepine therapy.
Steinhoff BJ; Stoll KD; Stodieck SR; Paulus W
Epilepsy Res; 1992 Mar; 11(1):67-70. PubMed ID: 1563340
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia.
Berghuis B; de Haan GJ; van den Broek MP; Sander JW; Lindhout D; Koeleman BP
Eur J Neurol; 2016 Sep; 23(9):1393-9. PubMed ID: 27333872
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
